Jay Skyler
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1437114691
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.0%), ownership interests and speaking fees — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 82.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $488,980 and has fallen 83.6% since, to $80,321 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $11,285 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$1.8M
- Sanofi-aventis U.S. LLC$216K
- Boehringer Ingelheim$30K
- Novo Nordisk AS$25K
- Sanofi US Services Inc.$24K
- Sanofi$23K
- plus $62K from 11 others
Across 5 payments — averaging $3030.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$13K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$758,10235%
- Speaking & faculty fees$362,18817%
- Grants$311,26814%
- Travel & lodging$83,8834%
- Food & beverage$4,7380%
- Ownership interest$646,58630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 32 | $1,787,042 |
| Sanofi-aventis U.S. LLC | 57 | $215,670 |
| Boehringer Ingelheim | 21 | $29,838 |
| Novo Nordisk AS | 13 | $25,404 |
| Sanofi US Services Inc. | 7 | $23,620 |
| Sanofi | 5 | $22,877 |
| Bayer | 26 | $18,331 |
| Novo Nordisk | 8 | $16,558 |
| Vertex | 7 | $12,917 |
| AbbVie | 1 | $8,525 |
| Eli Lilly | 2 | $3,125 |
| AstraZeneca | 1 | $1,343 |
| Boehringer Ingelheim International GmbH | 3 | $1,237 |
| Lexicon Pharmaceuticals, Inc. | 6 | $123 |
| Kowa Pharmaceuticals America, Inc. | 1 | $122 |
| Lifescan, Inc. | 1 | $17 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$634,880
- DEXCOM CGM$340,324
- DEXCOM G6 CGM SYSTEM$339,333
- NO PRODUCT DISCUSSED$63,534
- TOUJEO$63,312
- TZIELD$40,988
- JARDIANCE$30,606
- SOLIQUA 100/33$30,257
- SOTAGLIFLOZIN$15,416
- Kerendia$15,268
- LANTUS$6,630
- Non-Covered$2,467
- FARXIGA$1,343
- Livalo$122
How this compares
$2,166,764 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 14 | $322 |
| Atorvastatin Calcium | 17 | $309 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Miami
- Eugenio Angueira-SerranoMiami$603K
- Rodolfo GalindoMiami$229K
- Camillo RicordiMiami$128K
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.